Schedule 13D ownership disclosure
LB Pharmaceuticals Inc
Common Stock, $0.0001 par value per share · CUSIP: 50180M108
Event date: 2025-09-12
Reporting persons may disclose overlapping interests. Their amounts are shown individually and are not added into a filing total.
- Filing-level shares
- Unavailable
- Percent of class
- Unavailable
- Pontifax Management 4 G.P. (2015) Ltd.Reported CIK 0001726334
Shares: 1,411,681.00 · Class: 6.3%
- Pontifax VI G.P. L.P.
Shares: 1,411,681.00 · Class: 6.3%
- Ran Nussbaum
Shares: 1,411,681.00 · Class: 6.3%
- Tomer Kariv
Shares: 1,411,681.00 · Class: 6.3%
Amounts are as disclosed in this filing. Schedule type alone does not establish investment intent.
Source: SEC EDGAR filingFiling metadata
- Accession number
- 0001213900-25-091474
- Form type
- SCHEDULE 13D
- Filer
- LB PHARMACEUTICALS INC
- CIK
- CIK 1691082
- Filed
- Sep 25, 2025
- Reporting period
- Sep 12, 2025
- Description
- Schedule 13D beneficial ownership